Is Vaxart Stock a Buy?

Is Vaxart Stock a Buy?

Vaxart (NASDAQ: VXRT), a biotech company focused on the development of oral vaccines, had an underwhelming performance in the stock market in 2019 with its shares dropping by more than 80%. Vaxart's stock could see even better days ahead if it manages to develop a vaccine for COVID-19. On the flip side, though, investors have to consider the genuine possibility that its coronavirus vaccine efforts will flop, and the stock will lose much of its gains as a result.